Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.04 +1.24 (+3.90%)

Streaming Delayed Price Updated: 12:35 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗

December 31, 2025

Via Chartmill

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗

December 29, 2025

The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development.

Via Stocktwits

Topics Supply Chain

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

Genmab Portfolio Prioritization Update

December 29, 2025

From Genmab A/S

Via Business Wire

Analyst Expectations For Genmab's Future ↗

September 24, 2025

Via Benzinga

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

December 08, 2025

From Genmab A/S

Via Business Wire

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

December 07, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

December 06, 2025

From Genmab A/S

Via Business Wire

Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Genmab (GMAB) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗

November 18, 2025

Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.

Via Benzinga

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 18, 2025

From Genmab A/S

Via Business Wire

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Halozyme also boasts a 98 Composite Rating out of 99. The best growth stocks have a Composite of 90 or better.

Via Investor's Business Daily

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 10, 2025

Via Benzinga

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Genmab A/S

Via Business Wire

Why Is Genmab Stock Trading Lower On Monday? ↗

October 20, 2025

Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

October 18, 2025

From Genmab

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

October 07, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Why Genmab Stock Popped on Friday ↗

October 03, 2025

Two pundits raised their price targets on the company.

Via The Motley Fool

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

October 03, 2025

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Why Genmab Stock Was Marching Higher Today ↗

September 30, 2025

The company's latest asset purchase seems to be impressing analysts.

Via The Motley Fool

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

September 29, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough ↗

September 29, 2025

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V.

Via Benzinga

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus ↗

September 29, 2025

The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer.

Via Investor's Business Daily

Topics Government

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 03, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria ↗

September 03, 2025

Discover GMAB, a biotech stock matching Peter Lynch's GARP strategy. It offers strong earnings growth, a low PEG ratio, and excellent financial health for long-term investors.

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals ↗

September 01, 2025

Genmab (GMAB) is a high-value biotech stock with a low P/E ratio, strong financial health, and robust profitability, making it a standout undervalued opportunity.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.